glp-1/gip/glucagon triple agonist name 🎙️ NEW EPISODE: Retatrutide—The *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic
Description
SURPASS-CVOT will not compare tirzepatide to placebo as commonly done
It is not known if Saxenda passes into your breast milk
The trial met its primary endpoint, demonstrating that semaglutide 7.2 mg led to significantly greater weight loss at week 72 compared to placebo
This is commonly seen from any low fat or low calorie diet
Khang R, Park C, Shin JH
